Harvard Bioscience Stock Forecast, Price & News

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

How has Harvard Bioscience's stock been impacted by Coronavirus?

Harvard Bioscience's stock was trading at $2.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HBIO shares have increased by 131.6% and is now trading at $5.72.
View which stocks have been most impacted by COVID-19.

Are investors shorting Harvard Bioscience?

Harvard Bioscience saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 607,700 shares, an increase of 19.5% from the December 15th total of 508,500 shares. Based on an average daily volume of 161,800 shares, the short-interest ratio is currently 3.8 days. Currently, 1.7% of the company's stock are short sold.
View Harvard Bioscience's Short Interest.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Harvard Bioscience.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its quarterly earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to analyst estimates of $28.10 million. Harvard Bioscience had a negative net margin of 1.60% and a positive trailing twelve-month return on equity of 9.59%. During the same quarter in the previous year, the business earned $0.01 earnings per share.
View Harvard Bioscience's earnings history.

What price target have analysts set for HBIO?

0 brokerages have issued twelve-month target prices for Harvard Bioscience's stock. Their forecasts range from $9.00 to $9.00. On average, they expect Harvard Bioscience's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 57.3% from the stock's current price.
View analysts' price targets for Harvard Bioscience or view top-rated stocks among Wall Street analysts.

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the following people:

• James W. Green, Chairman, President & Chief Executive Officer
• Kenneth F. Olson, COO, Senior VP-Global Operations & Engineering
• Michael A. Rossi, Chief Financial Officer
• Don Stewart, Vice President-North Americas & APAC Sales
• Ryan Wallace, Vice President-Global Sales, Preclinical Systems

Who are some of Harvard Bioscience's key competitors?

Some companies that are related to Harvard Bioscience include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), Bio-Techne (TECH), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of HBIO's competitors.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AMH Equity Ltd (1.96%) and Strs Ohio (0.26%). Company insiders that own Harvard Bioscience stock include Alan I Edrick and James W Green.
View institutional ownership trends for Harvard Bioscience.

Which institutional investors are buying Harvard Bioscience stock?

HBIO stock was bought by a variety of institutional investors in the last quarter, including AMH Equity Ltd, and Strs Ohio. Company insiders that have bought Harvard Bioscience stock in the last two years include Alan I Edrick, and James W Green.
View insider buying and selling activity for Harvard Bioscience or or view top insider-buying stocks.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $5.72.

How much money does Harvard Bioscience make?

Harvard Bioscience has a market capitalization of $233.44 million and generates $102.10 million in revenue each year. The medical instruments supplier earns $-7.81 million in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Harvard Bioscience have?

Harvard Bioscience employs 444 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is www.harvardbioscience.com.

Where are Harvard Bioscience's headquarters?

Harvard Bioscience is headquartered at 84 OCTOBER HILL RD, HOLLISTON MA, 01746.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at [email protected], or via fax at 508-429-5732.